Compare Abeona Therapeutics Inc (ABEO) vs IQIYI Inc - ADR (IQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs IQIYI Inc - ADR — how do they compare? Abeona Therapeutics Inc trades at $7.56 (market cap $424.33M), while IQIYI Inc - ADR trades at $1.35 (market cap $1.31B). The key difference: IQIYI Inc - ADR is far larger — about 3.1× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, IQIYI Inc - ADR nearer its low. Which is the better fit depends on your goals.
| ABEO | IQ | |
|---|---|---|
Market Cap | $424.33M | $1.31B |
Sector | Health | Media |
52-Week High | $7.45 | $2.79 |
52-Week Low | $4.17 | $0.96 |
Enterprise Value | $279.23M | $2.89B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.
Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.
iQIYI (IQ) trades at $1.33, up 3.1% in 24 hours, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q1 2026 revenue of $915.2M, missing expectations, but beat EPS estimates. Valuation ratios show low P/S and P/B, but negative profitability metrics persist. Recent news highlights AI platform growth and leadership changes, with analyst consensus leaning buy.
Outlook: Potential upside exists from AI initiatives and cost controls, but risks include revenue declines, regulatory pressures, and negative cash flow projections. Investors should weigh low valuation against profitability challenges and China market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About IQIYI Inc - ADR
iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →
